IDH2 and central nervous system cancer: In addition, we could not study ctDNA mutations in the IDH2 gene, which accounts for nearly 10–15% of the total of IDH mutations in gliomas, although none of the 10 patients harbored IDH2 mutations in the primary tumor [48].